NexPlasmaGen receives financial support from the Québec Ministry of Economy, Innovation and Energy, and the Québec Breast Cancer Foundation | NexPlasmaGen
17165
post-template-default,single,single-post,postid-17165,single-format-standard,bridge-core-2.6.4,qode-page-transition-enabled,ajax_fade,page_not_loaded,,qode-theme-ver-24.9,qode-theme-bridge,disabled_footer_top,qode_header_in_grid,qode-wpml-enabled,wpb-js-composer js-comp-ver-7.7,vc_responsive

NexPlasmaGen receives financial support from the Québec Ministry of Economy, Innovation and Energy, and the Québec Breast Cancer Foundation

21 Apr NexPlasmaGen receives financial support from the Québec Ministry of Economy, Innovation and Energy, and the Québec Breast Cancer Foundation

Posted at 16:59h in Blog, Business by
0 Likes

Montreal / April 21, 2023 – NexPlasmaGen announces that it has received $511,186 in funding from the ministère de l’économie, de l’innovation  et de l’Énergie (MEIE) du Québec and the Québec Breast Cancer Foundation (QBCF) to conduct clinical safety trials with its Convertible Plasma Jet medical device, for breast cancer patients.

This funding comes from the MEI PSO technology maturation program – component 2d managed by Axelys. The project consists of Phase 1 clinical trials for the treatment of a tumor bed with cold plasma after a breast lumpectomy.

“Receiving this funding from institutions such as the MEI and the QBCF is truly an honor. This support is crucial to validate the safety of our device in breast cancer patients for the very first time,” said Dr. Valérie Léveillé, CEO of NexPlasmaGen.

ABOUT NEXPLASMAGEN

NexPlasmaGen is converging the emerging field of cold plasma biotechnology into personalized cancer treatment. We are developing high-precision cold plasma delivery systems with the potential to kill cancer cells while sparing surrounding healthy tissue. NexPlasmaGen’s first application is in the treatment of breast cancer. Its patented cold plasma medical device is used to improve patient outcomes in breast conserving therapy.

Contact

Valérie Léveillé, CEO/Founder

1-514-229-9458, valerie.leveille@nexplasmagen.com, https://nexplasmagen.com/

11 Comments
  • Skapa personligt konto
    Posted at 21:22h, 13 January Reply

    Your point of view caught my eye and was very interesting. Thanks. I have a question for you.

    • nexplasmagen
      Posted at 20:47h, 26 January Reply

      Thank you for your comment. please ask your question and we will be glad to answer it.

  • ustvarite racun na binance
    Posted at 09:06h, 14 January Reply

    Can you be more specific about the content of your article? After reading it, I still have some doubts. Hope you can help me.

    • nexplasmagen
      Posted at 20:47h, 26 January Reply

      Please feel free to ask me question so I can clarify our article.

  • Anm"al dig f"or att fa 100 USDT
    Posted at 15:56h, 20 January Reply

    Thanks for sharing. I read many of your blog posts, cool, your blog is very good.

    • nexplasmagen
      Posted at 20:46h, 26 January Reply

      thank you!

  • Тркеу
    Posted at 18:59h, 23 January Reply

    Thank you for your sharing. I am worried that I lack creative ideas. It is your article that makes me full of hope. Thank you. But, I have a question, can you help me?

    • nexplasmagen
      Posted at 20:46h, 26 January Reply

      Yes of course. We will try to help. What is your question?

  • Registrati su binance
    Posted at 17:14h, 26 January Reply

    Your point of view caught my eye and was very interesting. Thanks. I have a question for you.

    • nexplasmagen
      Posted at 20:46h, 26 January Reply

      Hello, please feel free to aks your question. thanks!

  • Angéline Ortaaslan
    Posted at 20:27h, 26 January Reply

    This is very intelligent work to do.

Post A Comment